Special Drug Use Surveillance for Adcetris Intravenous Infusion 50 Milligrams "Relapsed or Refractory CD30-positive Peripheral T Cell Lymphoma or Hodgkin Lymphoma (Only Pediatric Patients)"
Latest Information Update: 11 Oct 2024
At a glance
- Drugs Brentuximab vedotin (Primary)
- Indications Hodgkin's disease; Peripheral T-cell lymphoma
- Focus Adverse reactions
- Sponsors Takeda
Most Recent Events
- 11 Jan 2024 Status changed from active, no longer recruiting to completed.
- 30 Nov 2023 Planned End Date changed from 30 Sep 2023 to 31 Dec 2023.
- 30 Nov 2023 Status changed from completed to active, no longer recruiting.